key: cord-0269022-yz8ecfbt
authors: Weigert, A.; Bergman, M.-L.; Goncalves, L.; Godinho, I.; Duarte, N.; Abrantes, R.; Borges, P.; Brennand, A.; Malheiro, V.; Matoso, P.; Akpogheneta, O.; Kosack, L.; Cruz, P.; Nogueira, E.; Pereira, M.; Ferreira, A.; Marques, M.; Nunes, T.; Viana, J.; Demengeot, J.; Penha-Goncalves, C.
title: Longitudinal analysis of antibody responses to the Pfizer BNT162b2 vaccine in Patients Undergoing Maintenance Hemodialysis
date: 2021-07-22
journal: nan
DOI: 10.1101/2021.07.20.21260849
sha: 22341072f383ef2a3b0ccb021cf1e8a0657601b8
doc_id: 269022
cord_uid: yz8ecfbt

Background and objectives: Patients undergoing hemodialysis are at higher risk of developing severe complications upon SARS-CoV-2 infection and were prioritized in the Portuguese vaccination campaign. Immunogenicity of COVID-19 vaccines in hemodialyzed patients was not addressed by the phase 3 clinical trials leading to their emergency approval. Design, setting, participants, and measurements: We performed a prospective, longitudinal, cohort analysis of 156 hemodialyzed patients and 143 age-matched controls scheduled for BTN162b2 vaccine. Excluded from analysis were five patients previously diagnosed with SARS-CoV-2, three sero-positive for anti-SARS-CoV-2 N, two dropouts and two deaths. ELISA was used to quantify anti-full-length Spike IgG, IgM and IgA levels in sera collected at day of the first vaccine dose (t0); 3 weeks later (day of the second dose, t1); and 3 weeks after the second inoculation (t2). Results: Seroconversion after the first vaccine dose (t1) was remarkably low in patients, with positivity for anti-spike IgG, IgM and IgA antibodies of 29.4%, 12% and 41%, respectively. The second vaccine dose raised seroconversion to 90.9% and 83.9% for IgG and IgA, respectively, while IgM positivity remained unchanged. At t1 the anti-Spike IgG level was significantly lower in patients with ages below 70 years when compared to age-matched controls, showing a profile similar to aged individuals (above 70 years). Immunosuppression was associated with lower antibody responses along the vaccine schedule (p=0.005 at t1; p=0.008 at t2). Noteworthy, previous unresponsiveness to hepatitis B vaccination (75/129, 58% of patients negative for anti-HBs antibodies) did not correlate with humoral unresponsiveness to BTN162b2. Other clinical and laboratory parameters had marginal correlations with response to vaccination. Conclusions: The large majority of hemodialyzed patients showed IgG seroconversion upon BNT162b2 mRNA vaccination but a sizable proportion of patients presented poor responses. These results support further investigation into the relationship between vaccination, serologic response and host protection.

Seroconversion after the first vaccine dose (t1) was remarkably low in patients, with positivity for anti-spike IgG, IgM and IgA antibodies of 29.4%, 12% and 41%, respectively. The second vaccine dose raised seroconversion to 90.9% and 83.9% for IgG and IgA, respectively, while IgM positivity remained unchanged. At t1 the anti-Spike IgG level was significantly lower in patients with ages below 70 years when compared to age-matched controls, showing a profile similar to aged individuals (above 70 years). Immunosuppression was associated with lower antibody responses along the vaccine schedule (p=0.005 at t1; p=0.008 at t2). Noteworthy, previous unresponsiveness to hepatitis B vaccination (75/129, 58% of patients negative for anti-HBs antibodies) did not correlate with humoral unresponsiveness to BTN162b2.

Other clinical and laboratory parameters had marginal correlations with response to vaccination.

The large majority of hemodialyzed patients showed IgG seroconversion upon BNT162b2 mRNA vaccination but a sizable proportion of patients presented poor responses. These results support further investigation into the relationship between vaccination, serologic response and host protection.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260849 doi: medRxiv preprint

Patients receiving in-center hemodialysis treatment are at increased risk of SARS-Cov-2 infection as social distancing is compromised by common treatment spaces and shared transportation. Mortality of hemodialyzed patients with COVID-19 is higher (1) and they may pose an additional stress in hospitals dialysis capacity, as most of these patients receive dialysis treatments as outpatients. Although vaccination has been widely recommended to this specific population, the efficacy in long term antibody generation and the effectiveness in reducing transmission and severe infection is still uncertain. The reduction of 90% in the incidence of COVID-19 after vaccination with the Pfizer BNT162b2 vaccine in the general population (2, 3) or in SARS-Cov-2 RNA detection in vaccinated versus non-vaccinated health workers (4) might not be reproduced in vaccinated hemodialysis patients. Initial studies revealed success in antibody generation but reduced titers in comparison with healthy controls (5) (6) (7) . We evaluated the IgG, IgM and IgA anti-spike antibody response along the vaccination schedule defined for BTN162b2 mRNA vaccine and characterized responders and non-responders in our cohort of hemodialysis outpatients. In addition, responses to the BTN162b2 vaccine were compared to the hepatitis B vaccination response and to total immunoglobulin titers.

This study was approved by the Ethics committee of Davita in Portugal in compliance with the Declaration of Helsinki, and follows international and national guidelines for . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260849 doi: medRxiv preprint health data protection. All participants provided informed consent to take part in the study.

The study enrolled 156 patients with stage 5 chronic kidney disease (CKD) undergoing renal replacement therapy as outpatients at a hemodialysis clinic (Davita, Eurodial) in Óbidos, Portugal. An age-matched control cohort without kidney disease comprised 143 individuals randomly selected from a larger cohort of 1245 Health care workers and 146 nursing home residents (8). All Participants initiated BNT162b2 mRNA vaccination (Comirnaty®, Pfizer/BioNTech) according the established schedule of 2 doses with a 3 weeks interval. Venous blood was collected at the day of first vaccine dose (time 0, t0), 3 weeks later at the day of the second dose (t1), and 3 weeks after the second dose (t2) (Figure 1A and B) . Participants with evidence of COVID-19 infection were excluded [serum reactivity against SARS-CoV-2 nucleocapsid (N) at time of enrolment (n=3) or SARS-CoV-2 RNA positivity in RT-PCR test before enrolment (n=2) or during the collection time (n=3)]. Between t0 and t1, two patients died and two patients dropped-out of the study. Between t1 and t2, one patient was hospitalized with non-COVID-19 respiratory infection ( Figure   1A ). Clinical data was collected from medical records and from questionnaire.

The ELISA assay used to quantify IgG, IgM and IgA anti-full-length SARSCoV2 spike was adapted from (9) and semi-automized in a 384-well format, according to a protocol to be detailed elsewhere. Assay performance was determined by testing 1000 pre-pandemic sera and 40 COVID-19 patients diagnosed at least 10 days prior to sera . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) COVID-19 patients established that the assay is semi-quantitative and has a dynamic range of 3 logs titre. Each sample was assayed in duplicates and any identified discrepancies resolved by repeating the test. Antibodies against SARS-Cov-2 N antigen were measured by an electrochemiluminescence immunoassay (ECLIA), from Roche Diagnostics (Elecsys ® Anti-SARS-CoV-2) and total IgG, IgM and IgA at t2 were quantified using three immunoturbidimetric methods (PEG enhanced) from Siemens Healthineers, using Siemens Atellica CH Analyzer, following manufacturer instructions.

Quade test was used to analyze individuals in temporal series and pairwise group comparisons between different time points used the Wilcoxon signed-rank test CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260849 doi: medRxiv preprint correlation coefficient (R) ( Fig. 4 and Supplemental Figure 1 ). All statistical tests were carried out using established R scripts.

This longitudinal, prospective, cohort study enrolled 156 patients on hemodialysis, scheduled for BNT162b2 mRNA vaccination in January and February 2021; 143 participants adhered to the three collection times (Figure 1A and B). The median age was 72 years of age (y) (27-93) and females represented 32% of the cohort ( Figure   1C and D). Eleven patients (8.8%) were under therapies potentially affecting immune responses (including corticosteroids, immunosuppressors and chemotherapy) ( Table   1 ). The control cohort included 143 age-matched individuals with median age of 73y (30-96) and 53,1% females ( Figure 1C and D) .

Sera from hemodialyzed patients and controls were analyzed for specific anti-SARS-CoV-2-Spike antibodies (IgG, IgM and IgA) using ELISA calibrated with sera from COVID-19 patients, allowing discrimination of positive/negative antibody reactivity Isotype class analysis of anti-spike antibodies also revealed marked progression in . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. To explore the effect of age on humoral response to vaccination we divided both cohorts into two age groups, below 70y and above 70y ( Figure 2C -E, middle and right panels). We observed that elderly individuals present overall lower anti-spike IgG levels at t1, with equivalent responses in patients and controls (0.47 [0.28-1.00] in patients, and 0.52 [0.38-1.21] in controls, above 70). Remarkably, below 70y, the . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. Total IgG levels measured in 142 patients at t2, were not correlated with anti-Spike IgG levels (r=0.13, p-value=0.13) ( Figure 4C) . Likewise, total IgA and total IgM levels did not correlate with anti-Spike antibody responses (data not shown). Finally, we found weak but significant correlation (r=-0.27, p=0.001) between the ageadjusted Charlson comorbidity index and anti-Spike IgG levels at t2 ( Figure 4D) .

Reviewing clinical data of the thirteen subjects that remained anti-Spike IgG negative at t2 did not show significant over-representation of clinical conditions ( Table 1) .

Although among the non-responders there was a trend towards a higher percentage of patients with cardiac disease, patients using antithrombotic agents, rheumatic disease, use of non-steroidal anti-inflammatory drugs and cancer (including leukemia), the . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260849 doi: medRxiv preprint numbers are too small both for statistical significance and for pinpointing clinically relevant differences. Further, correlation analysis of relevant clinical pathology indicators including time in dialysis, KT/V as a measure of dialysis adequacy, and several inflammatory and nutritional parameters only reveal weak or non-significant effects on anti-Spike IgG levels ( Table 1 and Supplemental Figure 1) .

The presence of allograft and related use of immunosuppression was rare but overrepresented in IgG non-responders (one kidney and one liver allograft recipients) ( Table 1) . Conversely, twelve additional kidney allograft recipients who underwent nephrectomy and stopped immunosuppression responded to the BNT162b2 mRNA vaccine.

Among the non-responders, seven of the thirteen patients were older than 85 years of age. Of the three non-responders less than 60 years old, two had functioning allografts and were receiving immunosuppression. Nevertheless, the majority of the 13 patients did not present laboratory clues to inflammation, anemia, or alterations in nutritional parameters including serum albumin, or 25-hydroxycholecalciferol levels or normalized protein catabolic rate (nPCR).

Our results reveal that seroconversion following BNT162b2 initial dose is markedly lower in hemodialyzed patients when compared to reported antibody responses in the general population (8,10) and further suggest that after the second vaccine dose antispike IgG antibody is not detectable in 9,1% of patients. It is uncertain if other protective mechanisms are activated, for how long responders will be able to maintain adequate antibody titers and if additional doses are efficient in generating protection . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260849 doi: medRxiv preprint antedated the marked reduction of cases in the general population and was rather remarkable. Thus, even with suboptimal antibody response, these observations suggest that vaccination with the current scheme may nevertheless be highly effective in reducing lethality of COVID-19 in dialysis population.

The funding entities had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260849 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260849 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260849 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260849 doi: medRxiv preprint CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.20.21260849 doi: medRxiv preprint

Chronic kidney disease is a key risk factor for severe COVID-19: A call to action by the ERA-edta

Alroy-Preis S: Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

2 (15.4%) 6 (4.6%)Cancer in the last 5 years (non leukemia), n (%) 1